Compare Illumina, Inc. (ILMN) vs Sunrun Inc (RUN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Sunrun Inc — how do they compare? Illumina, Inc. trades at $278.17 (market cap $39.95B), while Sunrun Inc trades at $7.64 (market cap $1.83B). The key difference: Illumina, Inc. is far larger — about 21.8× Sunrun Inc's market cap, and Illumina, Inc. is trading nearer its 52-week high, Sunrun Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 83 Days and Sunrun Inc for 16 Days on average.
| ILMN | RUN | |
|---|---|---|
Market Cap | $39.95B | $1.83B |
Volume | 3,169,503 | 8,672,852 |
Sector | Health | Energy |
52-Week High | $293.69 | $21.41 |
52-Week Low | $91.00 | $7.59 |
Typical Hold Time | 83 Days | 16 Days |
Enterprise Value | $41.31B | $16.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ILMN trades at $264.40, down 1.25% on the day, but remains near its recent 52-week high of $278.99 (Defense World, 2026-10-01). The stock has surged 94.9% year-to-date (Zacks Investment Research, 2026-09-24), supported by strong earnings beats in recent quarters and a bullish technical trend. Fundamentals show a significant turnaround, with 2025 net income reaching $850 million after prior losses, though valuation ratios like a P/E of 49.36 are elevated. The pending inclusion in the S&P 500 (PRNewsWire, 2026-09-04) adds a positive catalyst.
The outlook is positive, driven by sequencing growth, AI integration in genomics, and improved profitability. However, risks include high valuation sensitivity, cost volatility, and competitive pressures in the life sciences sector. Analyst consensus is bullish with a 54% buy rating, but the average price target of $241 suggests limited near-term upside from current levels.
Sunrun (RUN) trades at $7.64, up 0.39% with a bearish technical outlook despite strong analyst support. The company shows mixed fundamentals with revenue growth to $3.5B in 2026 but declining net margins from 15.21% to 11.59%. Recent partnerships with SPAN and Tesla highlight innovation, but negative operating cash flow and high debt-to-asset ratio of 70.76% pose challenges.
The stock presents a value opportunity with low P/E (5.16) and P/B (0.52) ratios, supported by a $16.33 consensus price target. However, risks include persistent cash burn, solar industry headwinds from high borrowing costs, and volatile sentiment. Investors should weigh cheap valuation against execution risks in a capital-intensive sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Sunrun Inc
Sunrun Inc. is one of the largest residential solar, battery storage, and energy services companies in the United States. The company provides solar panel installations, battery backup systems, and energy management solutions to homeowners. Sunrun primarily uses a solar-as-a-service model, offering customers solar leases and power purchase agreements (PPAs), which allow homeowners to adopt solar energy with little to no upfront cost. The company's mission is to create a planet run by the sun.
Read more on RUN →
